Study identifier:D5162R00034
ClinicalTrials.gov identifier:NCT06068049
EudraCT identifier:N/A
CTIS identifier:N/A
An ambispective, non-interventional, multiple cohort study to assess the management of osimertinib treatment in patients with EGFRm non-small cell lung cancer under real-world conditions in Spain
Non-small Cell Lung Cancer
N/A
No
-
All
400
Observational
18 Years - n/a
Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Sept 2024 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Cohort 1 Patients diagnosed with locally advanced or metastatic NSCLC with activating EGFR mutations that received first line treatment with osimertinib (FLAURA regimen). | - |
Cohort 2 Patients with stage IB-IIIA NSCLC after complete tumour resection that has activating mutations in the EGFR (deletion of exon 19 or substitution of exon 21 [L858R]) that received adjuvant treatment with osimertinib (ADAURA regimen). | - |